Guggenheim Securities Initiates Merrimack Pharmaceuticals With Buy

Analysts at Guggenheim Securities initiated coverage on

with a Buy rating. The target price for Merrimack Pharmaceuticals is set to $15. Merrimack Pharmaceuticals shares have gained 72.46 percent over the past 52 weeks, while the S&P 500 index has surged 11.15 percent in the same period. Merrimack Pharmaceuticals' shares fell 0.52 percent to $11.46 in after-hours trading.